paul jackson Posted August 12, 2021 Share Posted August 12, 2021 With regards to Fisher's latest topical research (below), here is the study from the journal Cell for all you budding scientists out there: https://www.cell.com/cell/fulltext/S0092-8674(21)00757-1 Link to comment Share on other sites More sharing options...
nipper Posted August 31, 2021 Share Posted August 31, 2021 just for the sake of sentimentality ... CUV is the top performer today, up 10%, and over $37 a share. Link to comment Share on other sites More sharing options...
macgyver Posted September 19, 2021 Share Posted September 19, 2021 Well. Paul Jackson has been exposed as a fop. It appears the guy who posts regular financial analyses has called it right on the sp so far. Looking for $80 by the end of the year, farfetched? No, not if the last four weeks are anything to go by. Those newcomers new to Clinuvel would do well to head over to Sharetease. You will not get any valuable information, opinions here, or anything of worth for that matter. Just grizzled knobs bitter they lost a whole bunch of posters Link to comment Share on other sites More sharing options...
Diggy Posted September 23, 2021 Share Posted September 23, 2021 SUP MAC. Where's Kiwi? LOL Link to comment Share on other sites More sharing options...
nipper Posted November 8, 2021 Share Posted November 8, 2021 from the AFR: Clinuvel Pharmaceuticals, [seen by some to be] a market darling that has developed a drug for a rare skin disease for which it now faces competition from a Japanese rival, faces a second strike and a possible spill at its annual meeting. Quote Chairman Willem Blijdorp urged shareholders to back the board at the Wednesday AGM, arguing the board has taken steps to address concerns about the CEO pay raised at last year’s meeting by shareholders. Quote Proxy firm Ownership Matters told clients to vote against the remuneration report at the AGM on November 10. If 25 per cent or more shareholders vote against the pay report again after the first strike last year, a spill motion is triggered. Ownership Matters told institutional investors to vote against the spill motion, preferring to give the biotech an opportunity to mend its ways. Long serving CEO Dr Philippe Wolgen has a service agreement that comes to an end this year, leaving room for an overhaul. ............ down 8% Link to comment Share on other sites More sharing options...
nipper Posted January 5 Share Posted January 5 Oh, fickle markets. All the opinionating in the world cannot keep the SP from retracing. From mid twenties , the run that saw $43 by Sept 2021 seems to have come undone. Now back to $27. When is that patent running out? Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now